Fresenius Kabi Oncology share price history, delisted

Last announcements

The company's own last announcements before its shares stopped trading, routine notices left out.Share news and announcements

Dec 2013
- 31 Dec · Exit Offer (Delisting)
  DSP Merrill Lynch Ltd ("Manager to the Delisting Offer") on behalf of Fresenius Kabi (Singapore) Pte Ltd (“Acquirer”) has informed this Exit Offer Public Announcement ("Exit Offer PA") .... (opens in a new tab)
- 30 Dec · Updates
  Exit offer Public Announcement made by Fresenius Kabi (Singapore) Pte Ltd to the public shareholders of Fresenius Kabi Oncology Limited ("company") ("Delisting Offer"). (opens in a new tab)
- 20 Dec · Delisting
  Fresenius Kabi Oncology Limited has, with reference to the Delisting of the equity shares of the Company from the Exchange, submitted to the Exchange the details of the name, address and contact numbers of the Contact Person at RTA and at the Company for solving Investor queries post Delisting. (opens in a new tab)
- 20 Dec · Suspension and Delisting of Trading in Equity Shares
  Members of the Exchange are hereby informed that the trading in the equity shares of Fresenius Kabi Oncology Limited shall be suspended w.e.f. January 03, 2014 (i.e. w.e.f. closing hours of trading on January 02, 2014 ) on account of voluntary delisting pursuant to the SEBI (Delisting of Equity Shares) Regulations, 2009. The admission to dealings in securities of the said company shall be withdrawn (delisted) w.e.f. January 10, 2014. Further, It may be noted that SEBI has informed the Exchange vide its letter dated December 20, 2013 that they have filed an appeal in this matter in the Hon ble Supreme Court and the outcome of the same is awaited.
- 12 Dec · Management
  Dr. Patricia Grigoleit , Non-Executive Director of the Company, has resigned from the directorship of the Company with effect from December 11, 2013.
- 11 Dec · Management
  Dr. Patricia Grigoleit, Non - Executive Director of the Company, has resigned from the directorship of the Company with effect from December 11, 2013.

Daily closes since Jan 2007, BSE closes Jan 2007 to Jul 2010, adjusted for splits and bonuses

Daily close, ₹ per share

Results

Standalone, as consolidated accounts are on record for only 1 of the last ten years; ₹ crore, the charts by years to March, the table by quarter.Quarterly results

Quarter to Sep 2013, against the quarter before

Revenue: ₹96 Crdown 24.21%
Net profit: −₹45 CrQuarter to Jun 2013: ₹4.80 Cr
Net margin: −46.6%

Revenue by year

Net profit by year, a loss in red

Net profit
Loss

A loss in 1 of the 6 years shown

The years either side of a change of basis do not compare. From the year to Mar 2009, the company's revenue for that year, ₹275 Cr, differs from its quarters added, ₹299 Cr.

₹ crore	Dec 2011	Mar 2012	Jun 2012	Sep 2012	Dec 2012	Mar 2013	Jun 2013	Sep 2013
Revenue	128	122	133	165	205	93	127	96
Net profit	1	5	13	27	48	−8	5	−45
Net margin	1.1%	4.0%	9.8%	16.4%	23.6%	−8.3%	3.8%	−46.6%

Standalone. The last eight quarters. The latest is shaded.

Where the return came from

Yearly rates to Mar 2013, per-share figures restated for splits and bonuses.

Over	Return a year	Earnings growth	Change in P/E	Dividend yield
1 year	−29.0%	+58.1%	−55.1%	0.0%
3 years	−4.3%	+0.1%	−4.4%	0.0%
5 years	+10.8%	−11.8%	+25.6%	0.0%

Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add.

Recent sessions

The last 10 trading days to 2 Jan 2014, as traded on BSE.

Date	Open	High	Low	Close	Average price	Volume
2 Jan 2014	132.00	132.75	132.00	132.50	132.46	1,75,153
1 Jan 2014	131.20	132.50	131.20	132.05	132.02	2,02,740
31 Dec 2013	131.80	132.00	131.75	131.90	131.89	69,243
30 Dec 2013	131.65	132.00	131.20	132.00	131.95	3,80,448
27 Dec 2013	131.50	132.00	131.50	131.65	131.67	14,427
26 Dec 2013	132.00	132.00	131.10	132.00	131.98	5,31,224
24 Dec 2013	131.50	132.30	131.50	132.00	131.99	4,45,569
23 Dec 2013	131.50	132.80	131.10	132.20	131.77	39,651
20 Dec 2013	130.25	131.00	130.25	130.40	130.46	17,214
19 Dec 2013	131.35	131.35	130.40	130.55	130.45	4,217

Prices in ₹ per share as traded, not adjusted.

Company details

Legal name: Fresenius Kabi Oncology Limited
BSE code: 532545
ISIN: INE575G01010
Listed: Sep 2004
Face value: ₹1
Former symbols: FKONCO, DABURPHARM
Website: www.fresenius-kabi-oncology.com (opens in a new tab)
CIN: L24231DL2003PLC119441; Corporate identity number, the registrar of companies' code for it